<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01240356</url>
  </required_header>
  <id_info>
    <org_study_id>CLOTBUST-HF</org_study_id>
    <nct_id>NCT01240356</nct_id>
  </id_info>
  <brief_title>CLOTBUST Hands-Free: A Phase I/II Pilot Safety Trial</brief_title>
  <acronym>CLOTBUST-HF</acronym>
  <official_title>Combined Lysis of Thrombus in Brain Ischemia With Transcranial Ultrasound and Systemic T-PA-Hands-Free. A Phase I/II Pilot Safety Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of CLOTBUST-HF is to determine the safety of a novel, external Hands-Free
      transcranial Doppler (TCD) ultrasound system in healthy volunteers and ischemic stroke
      patients. If found to be safe, the widespread use of operator-independent,
      ultrasound-enhanced thrombolysis will allow the planning for a large Phase III efficacy
      trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ultrasound energy to enhance intravenous rt-PA thrombolysis is a promising novel treatment
      modality for ischemic stroke. Despite encouraging safety data utilizing diagnostic
      frequencies of transcranial Doppler (TCD) ultrasound, lack of widespread availability of
      trained personnel has limited its application.

      - The primary specific aim for this pilot phase I/II study is to assess the safety of a
      novel, external Hands-Free TCD ultrasound system. Safety of the new Hands-Free TCD system
      will first be assessed in healthy volunteers. Safety in these participants will be determined
      by detailed neurological and dermatological exams and MRI imaging of the brain. Next, safety
      of the device will be evaluated in two distinct sets of acute ischemic stroke patients: 0-3
      hour patients treated with standard IV rt-PA and 3-6 hour non-lytic, image-selected patients
      treated with sonolysis (with or without intravenous microbubbles). Among the healthy
      volunteers the primary measures of safety will be to have no detectable changes in a detailed
      neurological exam nor any blood- brain barrier (BBB) disruption or changes in permeability.
      Among both the 0-3 hour and 3-6 hour groups the primary measure of safety will be to not
      tolerate greater than a 10% rate of symptomatic intracerebral hemorrhage (sICH) within 24
      hours.

      * The primary hypothesis is that replacing conventional TCD ultrasound hand-held TCD
      technology with a Hands-Free system will be safe in healthy volunteers as well as acute
      ischemic stroke patients.

      If the device is found to be safe in either the 0-3 hour or 3-6 hour groups,

      - the secondary aims for this study will explore the rates of arterial recanalization in the
      0-3 hour and/or 3-6 hour groups, favorable outcomes, and clinical recovery. The secondary
      aims will assess the hypothesis is that Hands-Free TCD will display similar recanalization
      and early clinical recovery rates compared to available historical diagnostic TCD ultrasound
      controls exposed to conventional FDA-approved TCD technology.

      Data generated during this phase I/II trial will evaluate the safety of replacing an
      operator-dependent TCD device with an operator-independent unit. In turn, this will allow
      extensive availability of therapeutic ultrasound and improve enrollment into
      ultrasound-enhanced thrombolysis stroke trials.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants in Phase I Group With Blood-brain-barrier Disruption (BBB) as Measured by MRI of the Brain</measure>
    <time_frame>2-3 hours after treatment</time_frame>
    <description>Phase I : Imaging of the brain via MRI scans was performed to determine if the Hands-Free transcranial Doppler (TCD) system results in any BBB-disruption or deterioration in permeability.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety in Phase II Group as Measured by Incidence of Symptomatic Intracerebral Hemorrhage</measure>
    <time_frame>within 24 hours</time_frame>
    <description>Phase II: Determine if the Hands-Free TCD will not result in higher than 10% rate of symptomatic intracerebral hemorrhage (ICH) within 24 hours (defined as clinical worsening &gt; 4 NIH Stroke Scale (NIHSS) points and presence of hemorrhage on CT scan that in the opinion of the treating physician is causatively related to ICH on CT) in 0-3 hours acute stroke patients treated with intravenous tissue-type plasminogen activator (IV-t-PA).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants in Phase I Group With Neurological Deterioration as Measured by Neurological Examination</measure>
    <time_frame>2-3 hours after treatment</time_frame>
    <description>The neurological examinations comprised assessments of mental status and orientation, cranial nerve examination, muscle strength and tone, deep tendon reflexes, sensory testing, coordination, and gait.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants in Phase I Group With Adverse Events During and After Study Treatment With HF TCD</measure>
    <time_frame>2-3 hours after treatment</time_frame>
    <description>Phase I - A group of healthy volunteers will be assessed to determine the feasibility and activity of hands-free (HF) transcranial Doppler (TCD). Adverse events include subject complaints regarding discomfort of the device and dermatological adverse events as evidenced by a detailed physical examination of skin integrity post-insonation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in the Phase II Group That Show Arterial Recanalization as Measured Using Standard Transcranial Doppler Ultrasound Systems</measure>
    <time_frame>2-3 hours after treatment</time_frame>
    <description>Ischemic stroke patients: 2-hour rates of arterial complete and partial recanalization as measured using standard Transcranial Doppler Ultrasound systems.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in Phase II Group With Neurological Worsening as Determined by the NIH Stroke Scale</measure>
    <time_frame>within 90 days of enrollment</time_frame>
    <description>The National Institutes of Health Stroke Scale, or NIH Stroke Scale (NIHSS) is a tool used by healthcare providers to objectively quantify the impairment caused by a stroke. Each item on the NIHSS scores a specific ability between a 0 and 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment. The individual scores from each item are summed in order to calculate a patient's total NIHSS score. The maximum possible score is 42, with the minimum score being a 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in Phase II Group With Excellent Outcome as Measured by Modified Rankin Scale (mRS)</measure>
    <time_frame>at 3-months from enrollment</time_frame>
    <description>A modified Rankin Scale (mRS) score of 0 or 1 indicates an excellent outcome. The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The mRS scale ranks patients from 0 to 6 (0 is the best score, 6 is the worst score).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Phase I: Healthy Volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects without history of Central Nervous System Disease will receive 2-hours of hands-free 2-megahertz (MHz) transcranial Doppler ultrasound insonation continuously. A brain MRI with gadolinium will be performed before and after the ultrasound.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II: 0-3 hour Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ischemic stroke patients who present between 0-3 hours will receive 2-hours of hands-free 2-MHz transcranial Doppler ultrasound Continuously to the intracranial vessels.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>2-MHz transcranial Doppler ultrasound</intervention_name>
    <description>2-hours of hands-free ultrasound will be insonated continuously. A brain MRI with gadolinium will be performed before and after the ultrasound.</description>
    <arm_group_label>Phase I: Healthy Volunteers</arm_group_label>
    <other_name>transcranial Doppler Ultrasound</other_name>
    <other_name>ultrasound</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>2-MHz transcranial Doppler ultrasound insonation</intervention_name>
    <description>2-hours of hands-free ultrasound delivered to in the intracranial vessels.</description>
    <arm_group_label>Phase II: 0-3 hour Patients</arm_group_label>
    <other_name>transcranial Doppler ultrasound</other_name>
    <other_name>ultrasound</other_name>
    <other_name>sonothrombolysis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

        Phase I Safety (healthy volunteers):

          -  Presence of temporal windows as measured first by an FDA-approved diagnostic TCD
             device.

          -  Age ≥ 18 years old.

          -  Signed informed consent.

        Phase II (0-3 hours ischemic stroke patients):

          -  Disabling focal neurological deficit (NIHSS &gt; 4 points);

          -  No evidence of hemorrhage on non-contrast head CT scan;

          -  Intravenous rt-PA (0.9 mg/kg, 10% bolus 90% infusion over 1 hour, maximum dose 90 mg)
             infusion initiated within 3 hours of symptom onset;

          -  Diagnostic TCD completed and HF-TCD placed before rt-PA bolus.

          -  Diagnostic TCD confirms intracranial arterial occlusion of the middle cerebral artery
             (MCA), anterior cerebral artery (ACA), internal carotid artery (ICA), posterior
             cerebral artery (PCA) or distal basilar artery.

          -  Age ≥ 18 years old.

          -  Signed informed consent.

        Phase II (3-6 hours ischemic stroke patients):

          -  Measurable focal neurological deficit (NIHSS &gt; 4 points);

          -  No evidence of hemorrhage on non-contrast head CT scan;

          -  Diagnostic TCD confirms intracranial arterial occlusion of the middle cerebral artery
             (MCA), anterior cerebral artery (ACA), internal carotid artery (ICA), posterior
             cerebral artery (PCA) or distal basilar artery.

          -  Presence of neuroimaging defined mismatch (CT or MRI prior to enrollment)

               1. CT-perfusion

                    -  ≥ 20% difference between affected territories on Time to Peak (TTP) and
                       Cerebral Blood Volume (CBV) maps.

               2. MRI Diffusion-Perfusion mismatch

                    -  ≥ 20% difference between diffusion-weighted imaging (DWI) lesion and
                       territory of perfusion delay perfusion weighted imaging (PWI).

          -  Age ≥ 18 years old.

          -  Signed informed consent.

        EXCLUSION CRITERIA:

        Phase I Safety (healthy volunteers):

          -  History of any neurological disease affecting the central nervous system;

          -  Lack of temporal windows.

          -  History of renal disease or glomerular filtration rate (GFR) &lt; 60.

          -  Contraindication to MRI (e.g., pacemaker, spinal cord stimulator, severe
             claustrophobia)

        Phase II (0-3 hours ischemic stroke patients):

          -  Absent temporal windows in patients with anterior circulation ischemia;

          -  Intra-arterial thrombolysis;

          -  Patient refusal to give informed consent to participate in the CLOTBUST-HF trial;

          -  Contraindications for intravenous rt-PA (NINDS rt-PA Stroke Study Protocol)2.

          -  Phase II (3-6 hours ischemic stroke patients):

          -  Absent temporal windows in patients with anterior circulation ischemia;

          -  Intra-arterial thrombolysis;

          -  Patient refusal to give informed consent to participate in the CLOTBUST-HF trial;

          -  History of allergic response to Definity® microspheres or microbubbles currently being
             tested (MRX-801);

          -  Baseline imaging consistent with a malignant ischemic pattern (low CBV values or DWI
             territory &gt;100cc of tissue);

          -  Baseline MRI imaging demonstrating delayed perfusion of &gt; 8 seconds in &gt;100cc of brain
             parenchyma26;

          -  Patients receiving other investigational drugs, procedures, or therapies within 30
             days prior to study treatment;

          -  Significant concurrent medical/neurological conditions or deviation from normal
             laboratory test values at baseline that, in the opinion of the investigator, pose
             significant risk to the patient and warrant exclusion from the study;

          -  Known severe chronic obstructive pulmonary disease (COPD) (baseline oxygen saturation
             &lt; 80% on room air);

          -  Known right-to-left cardiac shunt.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James C. Grotta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Medical School-Houston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Medical School-Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Barlinn K, Barreto AD, Sisson A, Liebeskind DS, Schafer ME, Alleman J, Zhao L, Shen L, Cava LF, Rahbar MH, Grotta JC, Alexandrov AV. CLOTBUST-hands free: initial safety testing of a novel operator-independent ultrasound device in stroke-free volunteers. Stroke. 2013 Jun;44(6):1641-6. doi: 10.1161/STROKEAHA.113.001122. Epub 2013 Apr 18.</citation>
    <PMID>23598523</PMID>
  </results_reference>
  <results_reference>
    <citation>Barreto AD, Alexandrov AV, Shen L, Sisson A, Bursaw AW, Sahota P, Peng H, Ardjomand-Hessabi M, Pandurengan R, Rahbar MH, Barlinn K, Indupuru H, Gonzales NR, Savitz SI, Grotta JC. CLOTBUST-Hands Free: pilot safety study of a novel operator-independent ultrasound device in patients with acute ischemic stroke. Stroke. 2013 Dec;44(12):3376-81. doi: 10.1161/STROKEAHA.113.002713. Epub 2013 Oct 24. Erratum in: Stroke. 2014 Jan;45(1):e11.</citation>
    <PMID>24159060</PMID>
  </results_reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 8, 2010</study_first_submitted>
  <study_first_submitted_qc>November 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2010</study_first_posted>
  <results_first_submitted>January 27, 2014</results_first_submitted>
  <results_first_submitted_qc>May 17, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 23, 2016</results_first_posted>
  <last_update_submitted>May 17, 2016</last_update_submitted>
  <last_update_submitted_qc>May 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>James Grotta</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>transcranial doppler</keyword>
  <keyword>sonothrombolysis</keyword>
  <keyword>ultrasound</keyword>
  <keyword>stroke</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Phase I</title>
          <description>Non-stroke volunteers.</description>
        </group>
        <group group_id="P2">
          <title>Phase II</title>
          <description>Acute Ischemic Stroke patients received standard-doce intravenous tissue-type plasminogen activator (tPA) within 0-3 hours window.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>MRI contraindication</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Phase I</title>
          <description>Non-stroke volunteers.</description>
        </group>
        <group group_id="B2">
          <title>Phase II</title>
          <description>Phase II-20 patients with ischemic stroke treated with IV-tPA</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49" spread="16"/>
                    <measurement group_id="B2" value="63" spread="14"/>
                    <measurement group_id="B3" value="57" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants in Phase I Group With Blood-brain-barrier Disruption (BBB) as Measured by MRI of the Brain</title>
        <description>Phase I : Imaging of the brain via MRI scans was performed to determine if the Hands-Free transcranial Doppler (TCD) system results in any BBB-disruption or deterioration in permeability.</description>
        <time_frame>2-3 hours after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phase I</title>
            <description>Non stroke patients</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants in Phase I Group With Blood-brain-barrier Disruption (BBB) as Measured by MRI of the Brain</title>
          <description>Phase I : Imaging of the brain via MRI scans was performed to determine if the Hands-Free transcranial Doppler (TCD) system results in any BBB-disruption or deterioration in permeability.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety in Phase II Group as Measured by Incidence of Symptomatic Intracerebral Hemorrhage</title>
        <description>Phase II: Determine if the Hands-Free TCD will not result in higher than 10% rate of symptomatic intracerebral hemorrhage (ICH) within 24 hours (defined as clinical worsening &gt; 4 NIH Stroke Scale (NIHSS) points and presence of hemorrhage on CT scan that in the opinion of the treating physician is causatively related to ICH on CT) in 0-3 hours acute stroke patients treated with intravenous tissue-type plasminogen activator (IV-t-PA).</description>
        <time_frame>within 24 hours</time_frame>
        <population>Intention to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Phase II - Ischemic Stroke Patients</title>
            <description>Phase II - A group of 20 patients with ischemic stroke treated with IV-tPA</description>
          </group>
        </group_list>
        <measure>
          <title>Safety in Phase II Group as Measured by Incidence of Symptomatic Intracerebral Hemorrhage</title>
          <description>Phase II: Determine if the Hands-Free TCD will not result in higher than 10% rate of symptomatic intracerebral hemorrhage (ICH) within 24 hours (defined as clinical worsening &gt; 4 NIH Stroke Scale (NIHSS) points and presence of hemorrhage on CT scan that in the opinion of the treating physician is causatively related to ICH on CT) in 0-3 hours acute stroke patients treated with intravenous tissue-type plasminogen activator (IV-t-PA).</description>
          <population>Intention to Treat (ITT)</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants in Phase I Group With Adverse Events During and After Study Treatment With HF TCD</title>
        <description>Phase I - A group of healthy volunteers will be assessed to determine the feasibility and activity of hands-free (HF) transcranial Doppler (TCD). Adverse events include subject complaints regarding discomfort of the device and dermatological adverse events as evidenced by a detailed physical examination of skin integrity post-insonation.</description>
        <time_frame>2-3 hours after treatment</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 (Healthy Volunteers)</title>
            <description>Phase I - A group of non-stroke healthy volunteers.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants in Phase I Group With Adverse Events During and After Study Treatment With HF TCD</title>
          <description>Phase I - A group of healthy volunteers will be assessed to determine the feasibility and activity of hands-free (HF) transcranial Doppler (TCD). Adverse events include subject complaints regarding discomfort of the device and dermatological adverse events as evidenced by a detailed physical examination of skin integrity post-insonation.</description>
          <population>ITT</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants in the Phase II Group That Show Arterial Recanalization as Measured Using Standard Transcranial Doppler Ultrasound Systems</title>
        <description>Ischemic stroke patients: 2-hour rates of arterial complete and partial recanalization as measured using standard Transcranial Doppler Ultrasound systems.</description>
        <time_frame>2-3 hours after treatment</time_frame>
        <population>ITT - Percent of patients who had complete recanalization after treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase II - Iscehmic Stroke Patients</title>
            <description>Phase II - 20 patients with ischemic stroke treated with IV-tPA</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants in the Phase II Group That Show Arterial Recanalization as Measured Using Standard Transcranial Doppler Ultrasound Systems</title>
          <description>Ischemic stroke patients: 2-hour rates of arterial complete and partial recanalization as measured using standard Transcranial Doppler Ultrasound systems.</description>
          <population>ITT - Percent of patients who had complete recanalization after treatment.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" lower_limit="19" upper_limit="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants in Phase II Group With Neurological Worsening as Determined by the NIH Stroke Scale</title>
        <description>The National Institutes of Health Stroke Scale, or NIH Stroke Scale (NIHSS) is a tool used by healthcare providers to objectively quantify the impairment caused by a stroke. Each item on the NIHSS scores a specific ability between a 0 and 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment. The individual scores from each item are summed in order to calculate a patient's total NIHSS score. The maximum possible score is 42, with the minimum score being a 0.</description>
        <time_frame>within 90 days of enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phase II - Ischemic Stroke Patients</title>
            <description>Phase II - A group of 20 patients with ischemic stroke treated with IV-tPA</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants in Phase II Group With Neurological Worsening as Determined by the NIH Stroke Scale</title>
          <description>The National Institutes of Health Stroke Scale, or NIH Stroke Scale (NIHSS) is a tool used by healthcare providers to objectively quantify the impairment caused by a stroke. Each item on the NIHSS scores a specific ability between a 0 and 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment. The individual scores from each item are summed in order to calculate a patient's total NIHSS score. The maximum possible score is 42, with the minimum score being a 0.</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="0" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants in Phase II Group With Excellent Outcome as Measured by Modified Rankin Scale (mRS)</title>
        <description>A modified Rankin Scale (mRS) score of 0 or 1 indicates an excellent outcome. The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The mRS scale ranks patients from 0 to 6 (0 is the best score, 6 is the worst score).</description>
        <time_frame>at 3-months from enrollment</time_frame>
        <population>ITT with modified Ranking scores (mSR) at 90 days. % displayed is % with excellent outcome (mRS of 0-1).</population>
        <group_list>
          <group group_id="O1">
            <title>Phase II - Ischemic Stroke Patients</title>
            <description>Phase II - A group of 20 patients with ischemic stroke treated with IV-tPA</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants in Phase II Group With Excellent Outcome as Measured by Modified Rankin Scale (mRS)</title>
          <description>A modified Rankin Scale (mRS) score of 0 or 1 indicates an excellent outcome. The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The mRS scale ranks patients from 0 to 6 (0 is the best score, 6 is the worst score).</description>
          <population>ITT with modified Ranking scores (mSR) at 90 days. % displayed is % with excellent outcome (mRS of 0-1).</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" lower_limit="7" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants in Phase I Group With Neurological Deterioration as Measured by Neurological Examination</title>
        <description>The neurological examinations comprised assessments of mental status and orientation, cranial nerve examination, muscle strength and tone, deep tendon reflexes, sensory testing, coordination, and gait.</description>
        <time_frame>2-3 hours after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phase I: Healthy Volunteers</title>
            <description>Phase I - A group of 15 Non-stroke healthy volunteers.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants in Phase I Group With Neurological Deterioration as Measured by Neurological Examination</title>
          <description>The neurological examinations comprised assessments of mental status and orientation, cranial nerve examination, muscle strength and tone, deep tendon reflexes, sensory testing, coordination, and gait.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Phase I: Healthy Volunteers</title>
          <description>Phase I - 15 non-stroke healthy volunteers.</description>
        </group>
        <group group_id="E2">
          <title>Phase II - Ischemic Stroke Patients</title>
          <description>Phase II - 20 patient with ischemic stroke treated with IV-tPA</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Intracranial hemohhrage secondary to bacterial endocarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Cerebral edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Stroke progression/Nuero-worsening</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia/respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia/decreased hemoglobin and hematocrit</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Electrolyze imbalance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Elevated CK</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>New diagnosis of PFO</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Fewer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Elevated white blood count</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Utinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Asymptomatic ICH</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Elevated Coag lab test</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Creatinine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Tachypnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Right lung atelectasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Positive sputum culture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The last phase (Phase II: 3-6 hour non-lytic patients who presented between 3-6 hours and with evidence of mismatch on neuroimaging), was not completed. This portion of the study was not started as new published evidence suggested little value.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>James C. Grotta, MD</name_or_title>
      <organization>The University of Texas Health Science Center at Houston</organization>
      <phone>+1 (713) 500-7088</phone>
      <email>james.c.grotta@uth.tmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

